Tuesday, February 13, 2007 9:53:00 PM
Neither the shares of eXegenics common stock to be issued in the stock sale, or the shares to be issued to Messrs. Paganelli and Baron will be registered under the Securities Act of 1933, as amended (the “Securities Act”). As a result these shares will be “restricted securities” within the meaning of the Securities Act and may not be resold in the public market place in the absence of a registration statement covering the shares, or an exemption from the registration requirements under the Securities Act and any applicable state securities laws.
the Investors with its 51% interest would be considered a control group under SEC regulations. As such, the Investors eXegencis’ common stock would be restricted from sale in the public market under SEC Rule 144.
the Investors with its 51% interest would be considered a control group under SEC regulations. As such, the Investors eXegencis’ common stock would be restricted from sale in the public market under SEC Rule 144.
Recent OPK News
- OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 • GlobeNewswire Inc. • 04/21/2026 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:55 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:10:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:50:09 PM
- OPKO Health to Participate in the Jefferies Biotech on the Beach Summit • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:07:43 PM
- OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/26/2026 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:11:42 PM
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/19/2025 09:05:00 PM
- NextPlat Reports Third Quarter 2025 Results • PR Newswire (US) • 11/13/2025 01:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 08:12:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 08:11:05 PM
- OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 10/29/2025 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications • GlobeNewswire Inc. • 10/29/2025 12:00:00 PM
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers • GlobeNewswire Inc. • 10/28/2025 12:00:00 PM
- OPKO Health to Report Third Quarter 2025 Financial Results on October 29 • GlobeNewswire Inc. • 10/22/2025 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2025 08:02:57 PM
- Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses • PR Newswire (US) • 09/15/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2025 08:12:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2025 08:07:20 PM
- OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 07/31/2025 08:05:00 PM


